WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 563288
Description: ZYJ-34c is a histone deacetylase inhibitor (HDACi) with potent oral antitumor activities.
MedKoo Cat#: 563288
Chemical Formula: C31H42N4O7
Exact Mass: 582.3053
Molecular Weight: 582.69
Elemental Analysis: C, 63.90; H, 7.27; N, 9.62; O, 19.22
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ZYJ-34c; ZYJ 34c; ZYJ34c;
IUPAC/Chemical Name: 2-((3,3-dimethylbutanoyl)isoleucyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
InChi Key: DMFYWVSGUMHBCM-UHFFFAOYSA-N
InChi Code: InChI=1S/C31H42N4O7/c1-7-19(2)28(33-26(36)16-31(3,4)5)30(39)35-17-21-14-24(42-18-27(37)34-40)11-8-20(21)15-25(35)29(38)32-22-9-12-23(41-6)13-10-22/h8-14,19,25,28,40H,7,15-18H2,1-6H3,(H,32,38)(H,33,36)(H,34,37)
SMILES Code: CCC(C(C(N1CC2=C(CC1C(NC3=CC=C(OC)C=C3)=O)C=CC(OCC(NO)=O)=C2)=O)NC(CC(C)(C)C)=O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 582.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Yang H, Xu W, Li Y, Lan P, Zhang J, Zhang Y, Zhang C. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest. Anticancer Drugs. 2014 Aug;25(7):767-77. doi: 10.1097/CAD.0000000000000101. PubMed PMID: 24686006.
2: Zhang Y, Inks ES, Zhu M, Chou CJ, Fang H, Li M, Shen Y, Yi F, Xu W. Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study. RSC Adv. 2013 Nov 21;3(43). doi: 10.1039/C3RA43249A. PubMed PMID: 24273644; PubMed Central PMCID: PMC3836556.
3: Zhang Y, Liu C, Chou CJ, Wang X, Jia Y, Xu W. Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. Chem Biol Drug Des. 2013 Aug;82(2):125-30. doi: 10.1111/cbdd.12144. Epub 2013 Jul 1. PubMed PMID: 23581848; PubMed Central PMCID: PMC3723752.
4: Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J Med Chem. 2011 Aug 11;54(15):5532-9. doi: 10.1021/jm200577a. Epub 2011 Jul 11. PubMed PMID: 21714538.